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Abstract
Introduction: Breast cancer is a profoundly heterogeneous disease with respect to biologic and clinical behavior. 
Gene-expression profiling has been used to dissect this complexity and to stratify tumors into intrinsic gene-
expression subtypes, associated with distinct biology, patient outcome, and genomic alterations. Additionally, breast 
tumors occurring in individuals with germline BRCA1 or BRCA2 mutations typically fall into distinct subtypes.
Methods: We applied global DNA copy number and gene-expression profiling in 359 breast tumors. All tumors were 
classified according to intrinsic gene-expression subtypes and included cases from genetically predisposed women. 
The Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm was used to identify significant DNA 
copy-number aberrations and genomic subgroups of breast cancer.
Results: We identified 31 genomic regions that were highly amplified in > 1% of the 359 breast tumors. Several 
amplicons were found to co-occur, the 8p12 and 11q13.3 regions being the most frequent combination besides 
amplicons on the same chromosomal arm. Unsupervised hierarchical clustering with 133 significant GISTIC regions 
revealed six genomic subtypes, termed 17q12, basal-complex, luminal-simple, luminal-complex, amplifier, and mixed 
subtypes. Four of them had striking similarity to intrinsic gene-expression subtypes and showed associations to 
conventional tumor biomarkers and clinical outcome. However, luminal A-classified tumors were distributed in two 
main genomic subtypes, luminal-simple and luminal-complex, the former group having a better prognosis, whereas 
the latter group included also luminal B and the majority of BRCA2-mutated tumors. The basal-complex subtype 
displayed extensive genomic homogeneity and harbored the majority of BRCA1-mutated tumors. The 17q12 subtype 
comprised mostly HER2-amplified and HER2-enriched subtype tumors and had the worst prognosis. The amplifier and 
mixed subtypes contained tumors from all gene-expression subtypes, the former being enriched for 8p12-amplified 
cases, whereas the mixed subtype included many tumors with predominantly DNA copy-number losses and poor 
prognosis.
Conclusions: Global DNA copy-number analysis integrated with gene-expression data can be used to dissect the 
complexity of breast cancer. This revealed six genomic subtypes with different clinical behavior and a striking 
concordance to the intrinsic subtypes. These genomic subtypes may prove useful for understanding the mechanisms 
of tumor development and for prognostic and treatment prediction purposes.
Introduction
The accumulation of genomic aberrations is a fundamen-
tal part of solid-tumor development. Identification of
patterns of DNA copy-number alterations (CNAs) and
the genes that are targeted may reveal underlying mecha-
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Page 2 of 14nisms of disease evolution and potential candidates for
therapeutic intervention. Breast cancer (BC) is a pro-
foundly heterogeneous disease that encompasses several
distinct disease entities, in which correct stratification of
patients is critical for optimal disease management. Con-
ventional markers for prognostication or treatment pre-
diction or both include tumor size and lymph-node
involvement, histologic grade, estrogen (ER) and proges-
terone receptor (PgR) expression, as well as human epi-
dermal growth factor receptor 2 (HER2, HER2/neu,
ERBB2) amplification status. Recent development of
high-throughput molecular methods offers new opportu-
nities to capture the wide range of genomic and biologic
variability in tumors. A pioneering study by Perou et al.
[1] used a gene-expression signature to disclose five
intrinsic molecular subtypes of BC: basal-like, normal-
like, HER2-enriched, and luminal A and B, suggested to
reflect differences in cellular origin and divergent pro-
gression of tumors. Subsequent analysis confirmed the
relevance of these molecular subtypes by showing corre-
lations to clinical parameters and overall survival (OS)
[2].
A study of BC pathophysiology approached the subject
of BC heterogeneity by linking transcriptional and
genomic profiles [3]. By classifying tumors according to
their patterns of CNA, three groups were identified and
referred to as the 1q/16q, amplifier, and complex sub-
types. Tumors of the 1q/16q genomic subtype showed
better disease-specific survival as compared with the
amplifier and complex subtypes, whereas tumors with a
basal-like gene-expression profile were found predomi-
nantly within the complex genomic subtype [3].
In the present study, we analyzed high-resolution
genomic data from array-comparative genomic hybrid-
ization (aCGH) analysis of 359 BCs to gain further insight
into patterns of CNA and loci that are specifically tar-
geted by focal amplification or homozygous deletion. We
combined these results with gene-expression data to
reveal underlying mechanisms of disease evolution to
highlight genomic heterogeneity in BC. Hierarchical clus-
tering analysis of significant genomic lesions revealed
genomic subtypes that displayed different clinical out-
comes and high similarity to the intrinsic gene-expres-
sion subtypes previously described [4]. Additionally,
tumors from BRCA1 and BRCA2 mutation carriers were
found in distinct genomic subtypes. In conclusion, we
show that the genomic landscape of BC reveals subtypes
that reflect biologic and clinical behavior.
Materials and methods
Patients and tumor material
Freshly frozen breast-tumor tissues (n = 359) were
obtained from the Southern Sweden Breast Cancer
Group tissue bank at the Department of Oncology, Skåne
University Hospital, Lund, The Helsinki University Cen-
tral Hospital, and Landspitali University Hospital. Of the
359 tumors, 346 were primary tumors, and the remaining
cases were either local recurrences or lymph node metas-
tases. Median OS follow-up time for patients from whom
primary tumors were available was 8.1 years (range, 0.24
to 32 years). Tumor and patient characteristics are sum-
marized in Table 1. Patients were diagnosed over a longer
time period at different institutions and consequently not
uniformly treated. The study was approved by the
regional Ethical Committee in Lund (reg. no. LU240-01
and 2009/658), waiving the requirement for informed
consent for the study, the Icelandic Data by the Protec-
tion Committee and the National Bioethics Committee of
Iceland, and the Finnish Data by the Helsinki University
Central Hospital Ethical Committee (207/E9/07). For Ice-
landic and Finnish patients, written informed consent
was obtained according to the national guidelines.
Gene-expression analysis
Global gene-expression analysis of breast tumors was
performed by using oligonucleotide microarrays (Gene
Expression Omnibus, GEO, [5] platform GPL5345) pro-
duced at the SCIBLU Genomics Centre at Lund Univer-
sity, Sweden [6], as described [7]. Data analysis and
normalization [8] of the 359 tumors were performed,
together with 218 other breast samples, as described
(Additional File 1). Tumors were classified according to
the intrinsic molecular subtypes reported by Hu et al. [4],
a proliferation gene module [9], and a genomic-grade sig-
nature [10], as described [11] (Additional File 1). Gene-
expression data for all 359 tumors are available through
GEO as GSE22133.
aCGH analysis
BAC microarrays (GEO platform GPL4723) comprising
approximately 32,000 clones were produced by the SCI-
BLU Genomics Centre, Lund University, Sweden, as
described [7]. Labeling, hybridization, image analysis,
and initial data analysis were performed as described [7].
Technical replicate experiments were performed on 15
tumors. Copy-number estimates (log2 ratios) for each
array were normalized [12], and replicated samples were
merged after normalization. Breakpoint analysis was per-
formed by using circular binary segmentation (CBS) with
α = 0.01 [13]. Only segments of four or more BAC probes
were used in further analyses. Gains and losses were
detected by applying sample adaptive thresholds, derived
from 250-kbp smoothed data, to CBS log2 ratios, as
described [12]. Recurrent high-level amplifications were
defined as occurring in > 1% of tumors with a CBS log2
ratio ≥1. The fraction of the genome altered (FGA) was
calculated as described [14]. CGH data for all 359 tumors
are available through GEO as GSE22133.
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Genomic Identification of Significant Targets in Cancer
(GISTIC) [15] was used to identify significant amplifica-
tion and deletion peaks in the 359 tumors, as described
(Additional File 1). Student's t test performed on average
scaled log2 ratios for significant GISTIC regions were
used to identify regions associated with different clinical
variables or molecular subtypes. Hierarchical clustering
of significant GISTIC peaks was performed by using
Pearson correlation and complete linkage on average
scaled log2 ratios for each peak. Genomic coordinates for
GISTIC regions are mapped to the UCSC Human
Genome browser build 17 [16].
Construction of gene-expression centroids based on 
genomic subtypes
Gene-expression centroids for genomic subtypes were
created based on genes used for classification according
to the molecular subtypes by Hu et al. [4] (Additional File
1). The centroids were subsequently applied to a previ-
ously reported [14] combined BC data set (n = 1,881
tumors) comprising 11 public BC data sets generated on
Affymetrix U133A arrays, including the Chin et al. data
set [3] (Additional File 1). Complementary aCGH data for
the Chin et al. data set were processed and analyzed as
described [17].
Correlation of gene-expression data with genomic 
aberrations
Gene-expression data were compared with GISTIC
aCGH log2 ratios for genomic subtypes by using Pearson
correlation, as described [7]. GISTIC regions were
expanded by one BAC probe in each direction to include
borderline genes. A correlation cut-off representing a P
value = 0.05 obtained from 100 permutations of aCGH
sample labels was used to identify significantly correlated
genes in GISTIC regions. Global correlation analysis for
genomic subtypes by using genes mapped to individual
BAC probes was performed similarly, with one modifica-
tion; CBS log2 ratios were used for individual BAC
probes.
Survival analysis
Univariate and multivariate regression analyses of overall
survival (OS) and distant metastasis-free survival
(DMFS) were performed in R [18] by using the Survival
package. OS or DMFS was the end point. Survival curves
were compared by using Kaplan-Meier estimates and the
Table 1: Patient and tumor characteristics for the 359 
tumors
Number of tumors 359
Number of primary tumors 346
Number of primary BRCA1-mutated tumors 17
Number of primary BRCA2-mutated tumors 31
Number of primary familial non-BRCA1/2 tumors 126
Tumor size
≤20 mm 145 (45%)
> 20 mm 175 (55%)
Mean size mm (SD) 25.8 (15)
Histologic grading
Grade 1 26 (11%)
Grade 2 100 (43%)
Grade 3 106 (46%)
Estrogen-receptor status
Positive 227 (66%)
Negative 119 (34%)
Progesterone-receptor status
Positive 194 (57%)
Negative 149 (43%)
Lymph-node status
Negative 190 (58%)
Positive 137 (42%)
Age
Median age, years (range) 49 (27-88)
< 50 years 182 (51%)
≥ 50 years 174 (49%)
Classification according to Hu et al. [4]
Basal-like 79 (22%)
Normal-like 34 (9%)
HER2-enriched 34 (9%)
Luminal A 95 (26%)
Luminal B 70 (19%)
Unclassified 47 (13%)
Overall survival
Median overall survival in years (range) 8.1 (0.24-32)
Median overall survival in years for 
patients still alive (range)
12.8 (1.55-20.2)
Survival is given for the 346 patients from whom primary tumors 
were available.
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rank tests and regression analyses, if not otherwise speci-
fied. Tick marks in Kaplan-Meier plots indicate censored
follow-up.
Results
Comprehensive DNA copy-number analysis of BC
We used a tiling BAC array CGH to survey genome-wide
CNAs in BC from BRCA1 (n = 22) and BRCA2 mutation
carriers (n = 32), non-BRCA1/2 familial (n = 132), and
sporadic cases (n = 173). The overall pattern of DNA
CNAs displayed an extensive heterogeneity with most
frequent CNAs on chromosomes 1q, 8q, and 16q (Figure
1). The GISTIC algorithm [15] was used to identify
genomic changes that represented statistically significant
events by using all 359 tumors. GISTIC identified 66
regions of gain and 67 regions of loss (Figure 1, Addi-
tional File 2).
The most frequent high-level amplification peaks were
found on chromosomes 17q12 (13%), 8p12 (7%), 8q24.21
(6%), 11q13.3 (6%), and 11q13.5 (4%), encompassing
known oncogenes such as HER2, MYC, CCND1, and
PAK1 (Table 1 in Additional File 3). To identify coampli-
fied regions, we selected loci amplified in at least three
cases and determined the fraction of coamplified samples
(Figure 2a). Amplifications located on the same chromo-
some or chromosomal arm were more commonly coam-
plified; however, chromosomes 11q13 and 8p12 were also
coamplified in a significant fraction (Figure 2a). Addi-
tionally, chromosome 12q15 was found to be coamplified
with 8p12 and 11q13. Several other loci were coamplified
but contained too few cases to draw any reliable conclu-
sions. As expected, the coamplification pattern also was
evident on the gene-expression level, pinpointing novel
and known target genes (Figure 2b).
In a subsequent step we aimed to identify target genes
within high-level amplifications. In total, we found 31 loci
affected by high-level amplifications. Integration of gene-
expression data with DNA copy-number data revealed a
number of candidate genes in which mRNA expression
was significantly correlated with gene dosage. Among sig-
nificantly correlated genes were known oncogenes, such
as HER2, FGFR1, CCND1, MYC, and MDM2; however,
we also found, for example, MDM4, ELK4, PTPRK,
GAB2, and RAB22A to be significantly correlated (Table
2). Among the top significant deletion GISTIC peaks
were chromosomes 9p21.3 and 10q23.31, encompassing
the CDKN2A and PTEN genes, respectively (Additional
File 2).
Molecular classification of BC by using DNA copy-number 
alterations
BC has been divided into intrinsic subtypes by using
gene-expression profiling [1,2]. Consistent with previous
Figure 1 Copy-number alterations (CNAs) observed in 359 breast cancers. Blue regions indicate positions of significant genomic aberrations (n 
= 133) identified by Genomic Identification of Significant Targets in Cancer (GISTIC) analysis. Green corresponds to loss, and red, to gain. Most common 
CNAs are observed on chromosomes 1q, 8p, 8q, 11q, and 16q, as indicated in the figure.
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Figure 2 High-level amplifications in breast cancer (BC). (a) Coamplification patterns in BC. For each amplification (vertical axis), the fraction of 
samples with a coamplification (horizontal axis) is indicated in each box. Coamplification fractions smaller than 20% are excluded: for example, 30% 
of all 12q15-amplified samples also have 8p12 amplification, whereas the fraction of 8p12-amplified samples with 12q15 amplification is < 0.2 and is 
not displayed. (b) Overview of the coamplification pattern in chromosomes 8p12, 11q13, and 12q15. Amplification pattern is also evident on a gene-
expression level, where a number of genes show a significant relation to gene-dosage effects.
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Page 6 of 14reports [3,19-21], we found several chromosomal regions
that were differentially altered between the intrinsic
gene-expression subtypes, as well as for several clinical
parameters (Figures S1 to S3 in Additional File 3). We
used GISTIC regions derived from DNA copy-number
data and hierarchical clustering to divide our cohort into
six subtypes characterized by different FGA levels and
CNAs (Figure 3a, b; Table 3; Additional File 4; Figure S4
in Additional File 3). To further characterize the identi-
fied genomic subtypes, we used available classification
according to the intrinsic gene-expression subtypes, as
well as other signatures derived from gene-expression
analysis of all tumors.
Four of the genomic subtypes displayed striking simi-
larity to previously described intrinsic subtypes derived
from gene-expression profiling. The 17q12 subtype com-
prised 67% of all cases with HER2 amplification (seg-
mented log2 ratio > 0.5), and 88% of all HER2-enriched
intrinsic subtype-classified cases were found in this
genomic subgroup. The basal-complex subtype included
mainly basal-like classified tumors, as well as 77% of all
BRCA1-mutated tumors. Furthermore basal-complex
Table 2: Regions amplified with a frequency of >1% in the 359 tumors
Amplified region Percentage of amplified samples Significantly correlated genes
1q21.1 1.1 BCL9, ACP6
1q32.1-q32.2 1.9 BTG2, ATP2B4, SOX13, GOLT1A, PLEKHA6, PPP1R15B, MDM4, RBBP5, RIPK5, ELK4, 
RAB7L1, SRGAP2, IKBKE, LGTN, DYRK3, MAPKAPK2,
6q21 1.4 BVES, AIM1
6q22.33-q23.1 1.1 PTPRK, L3MBTL3
8p12-p11.23 5.8 ZNF703, SPFH2, PROSC, RAB11FIP1, ADRB3, BAG4, PPAPDC1B, WHSC1L1, FGFR1
8q22.2-q22.3 3.1 VPS13B, RNF19, ANKRD6, GRHL2, EDD1, AZIN1, ATP6V1C1, FZD6, SLC25A32
8q23.3-q24.11 6.1 TRPS1, THRAP6, EXT1
8q24.13-q24.22 6.7 ZHX1, ATAD2, C8orf32, FBXO32, TMEM65, TRMT12, RNF139, TATDN1, KIAA0196, 
C8orf36, TRIB1, FAM84B, MYC, DDEF1 
10p15.3 1.1 PFKP, PITRM1
10p14 1.4
10q22.3 1.4 POLR3A, RAI17, PPIF
11q13.3-q13.4 6.4 CCND1, FADD, PPFI1A, CTTN
11q13.5-q14.1 3.6 PHCA, CAPN5, MYO7A, PAK1, HBXAP, ALG8, LOC283219, GAB2
12p13.33 1.7 JARID1A, WNK1, RAB6IP2, FBXL14, WNT5B, ADIPOR2, DCP1B
12p13.31 1.4 CD9, TNFRSF1A, LTBR, TAPBPL, MRPL51, NOL1, CHD4, ING4, ZNF384, COPS7A, MLF2, 
PTMS, USP5, SPSB2, ENO2, ATN1, PTPN6, PHB2, C1 S, C1RL, CLSTN3, PEX5
12q15 1.9 MDM1, NUP107, SLC35E3, MDM2, CPSF6, YEATS4, FRS2, CCT2, CNOT2
17q11.2 3.6 UNC119, PIGS, ALDOC, SPAG5, KIAA0100, SDF2, SUPT6 H, RAB34, NEK8, ERAL1, FLOT2, 
PHF12, LOC116236, GIT1, ANKRD13B, CORO6, SSH2
17q12.1-q21.1 13.6 FBXL20, PPARBP, STARD3, PERLD1, HER2, C17orf37, GRB7, GSDML, ORMDL3, PSMD3, 
THRAP4 
17q21.33 4.2 LOC81558, ITGA3, PDK2, PPP1R9B, XYLT2, MRPL27, FLJ20920, RSAD1, EPN3, ABCC3, 
ANKRD40, TOB1
17q23.2 3.1 TRIM25, AKAP1, MSI2
17q23.2 3.1 TMEM49, TUBD1, ABC1, USP32, APPBP2, BCAS3
17q23.3-q24.1 2.5 CYB561, WDR68, MAP3K3, LYK5, DDX42, FTSJ3, PSMC5, SMARCD2, ERN1, POLG2, 
DDX5, SMURF2
19p13.13-p13.2 1.1 SIPA1L3, PPP1R14A, SPINT2, YIF1B, EIF3S12
19p13.2 1.1 FBL, PSMC4, FLJ36888, PLD3
19q13.42 1.4 SUV42OH2, KLP1, ZNF579, FLJ14768, ZNF524, LOC147808, ZNF580, ZNF581
20q13.31-q13.32 1.1 RAE1, RNPC1, RAB22A, VAPB, STX16, GNAS, TH1L, CTSZ
Genes with significant correlation (P < 0.05) between mRNA expression and DNA copy-number status are indicated for each region.
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percentages, and higher correlation to a genomic-grade
signature (Figure 3a). The luminal-simple subtype
included mainly luminal A-classified tumors (72%) and
was predominantly characterized by frequent losses on
16q, and gains on 1q and 16p. Furthermore, cases in this
subtype displayed lower FGA levels, S-phase fractions,
and genomic grade correlation. Finally, the luminal-com-
plex subtype included 69% of all luminal B-classified
cases, and 78% of all BRCA2-mutated tumors, but also
33% of all luminal A subtype-classified tumors. Moreover,
two groups of tumors displayed mixed intrinsic subtype
characteristic and heterogeneous genomic profiles (the
amplifier and mixed subtypes). The mixed subtype
showed heterogeneous losses across several chromosome
arms, most frequently on 8p, 13q, and 17p, together with
frequent gain on 1q (~60%) (Additional File 4). The
amplifier subtype contained 48% of the 8p12-amplified
cases (segmented log2 ratio > 0.5) as well as frequent gain
of 1q, 11q13, 16p, 19p, and 19q and frequent losses on 8p,
11qter, 16q, and 17p (Additional File 4). Furthermore, the
amplifier contained the highest fraction of luminal B-
classified cases after the luminal-complex subtype. How-
ever, several GISTIC regions distinguished amplifier-
classified cases from luminal-complex cases in a super-
vised analysis (Figure S5 in Additional File 3). Interest-
ingly, 31% of all luminal-complex samples harbored 8p12-
amplification; however, these tumors displayed differ-
ences in the genomic pattern compared with 8p12-ampli-
fied tumors in the amplifier subclass. First, 8p12-
amplified tumors in the luminal-complex subtype
showed higher FGA compared with 8p12-amplified
Table 3: Patient and tumor characteristics for the six genomic subtypes
Basal-complex
n (%)
17q12
n (%)
Luminal-complex
n (%)
Luminal-simple
n (%)
Amplifier
n (%)
Mixed
n (%)
Group size 67 51 105 46 52 38
Hereditary status
BRCA1-mutated 17 (25) 0 1 (1) 0 2 (4) 2 (5)
BRCA2-mutated 5 (7) 1 (2) 25 (24) 0 0 1 (3)
Familial 15 (22) 19 (37) 38 (36) 23 (50) 29 (56) 8 (21)
Sporadic 30 (45) 31 (61) 41 (39) 23 (50) 21 (40) 27 (71)
Clinical parameters
ER+ 7 (10) 19 (37) 91 (87) 44 (96) 40 (77) 26 (68)
ER- 56 (84) 29 (57) 11 (10) 2 (4) 10 (19) 11 (29)
LN+ 19 (28) 25 (49) 42 (40) 12 (26) 20 (38) 19 (50)
LN- 43 (64) 19 (37) 50 (48) 32 (70) 28 (54) 18 (47)
Mean tumor size (mm ± SD) 27 ± 12 31 ± 21 26 ± 17 21 ± 10 25 ± 13 25 ± 11
Histologic grade 1 1 (1) 1 (2) 5 (5) 9 (20) 8 (15) 2 (5)
Histologic grade 2 5 (7) 14 (27) 31 (30) 21 (46) 19 (37) 10 (26)
Histologic grade 3 42 (63) 19 (37) 26 (25) 4 (9) 9 (17) 6 (16)
Molecular subtypes by Hu et al. [4]
Basal-like 56 (84) 5 (10) 4 (4) 0 8 (15) 6 (16)
HER2-enriched 0 30 (59) 3 (3) 0 0 1 (3)
Luminal B 1 (1) 3 (6) 48 (46) 1 (2) 12 (23) 5 (13)
Luminal A 1 (1) 6 (12) 31 (30) 33 (72) 12 (23) 12 (32)
Normal-like 3 (4) 6 (12) 3 (3) 6 (13) 10 (19) 6 (16)
Unclassified 6 (9) 1 (2) 16 (15) 6 (13) 10 (19) 8 (21)
FGA (mean %)
Overall FGA (%) 53 26 37 19 31 29
Gain FGA (%) 18 12 15 9 15 12
Loss FGA (%) 34 14 22 10 16 18
ER, Estrogen receptor; FGA, fraction of the genome altered; LN, lymph node.
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Figure 3 Unsupervised analysis of Genomic Identification of Significant Targets in Cancer (GISTIC) regions identifies six CGH subgroups of 
breast cancer (BC) associated with different clinical and molecular characteristics. (a) Hierarchic clustering of 133 GISTIC regions identifies six 
subtypes with different clinical and molecular characteristics, and genomic aberrations. Horizontal dashed line for S-phase indicates the average 
across all samples. (b) Fraction of the genome altered (FGA) for genomic subtypes indicating that basal-complex samples are genomically unstable, 
whereas luminal-simple tumors are genomically stable. (c) Overall survival (OS) for 339 patients, for whom primary tumors were available, classified 
according to genomic subtypes, mirrors results obtained for the intrinsic gene-expression subtypes.
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Page 9 of 14tumors in the amplifier subtype (P = 0.02; t test). Second,
in the amplifier subtype, 86% and 71% of 8p12-amplified
tumors showed coamplification of the 11q13.5 and
11q13.3 GISTIC regions, respectively, as compared with
29% and 17% of 8p12-amplified tumors in the luminal-
complex subtype.
To investigate whether the identified genomic subtypes
showed an association with the outcome, we performed
Kaplan-Meier analyses by using OS as end point. Not sur-
prisingly, significant differences in OS between genomic
subtypes were observed, with the luminal-simple subtype
having the best outcome, and the 17q12 subtype, the
worst outcome (Figure 3c).
Association of BRCA1/2 mutation status and genomic 
subtypes
The basal-complex and the luminal-complex subtypes
contained 77% of all BRCA1- and 78% of all BRCA2-
mutated tumors, respectively. Interestingly, by using
supervised analysis, no GISTIC region was found to differ
significantly between BRCA1 and non-BRCA1 tumors in
the basal-complex subtype, although the former showed a
significantly higher FGA (P = 0.01; t test). The five
BRCA1-mutated tumors falling outside the basal-com-
plex subtype did not differ significantly from other
BRCA1 tumors regarding FGA, S-phase fraction or
genomic grade correlation, with the exception that two of
five tumors were ER positive. BRCA2 tumors in the lumi-
nal-complex subtype were characterized by losses on
3p21.31, 3p14.1, 6q16.2, 13q14.2, 14q24.3, and 22q13.31
and gains on 17q25.3 compared with non-BRCA2 tumors
in the same genomic subtype, whereas the latter showed
more-frequent gain of 11q13.3 (Figure 4a). Again, BRCA2
tumors in the luminal-complex subtype showed signifi-
cantly higher FGA than did non-BRCA2 tumors in this
subtype (P = 0.01; t test). The seven BRCA2-mutated
tumors not belonging to the luminal-complex subtype
were found in the basal-complex (n = 5), 17q12 (n = 1),
and mixed (n = 1) subtypes. BRCA2 tumors in the basal-
complex subtype were ER-negative (80%), showed higher
FGA, higher genomic grade correlation than luminal-
complex BRCA2 tumors, and displayed CNAs more simi-
lar to BRCA1 tumors.
DNA copy-number alterations divide luminal breast cancer 
in two entities
Supervised analyses were performed to investigate differ-
ences in characteristic alterations between luminal-com-
plex and luminal-simple tumors. Luminal-simple tumors
were primarily characterized by frequent loss on 16q,
whereas luminal-complex tumors were characterized by
losses on 3p, 8p, 9p, 11q25, and 13q and gains on 8q,
11q13.3, and 17q (Figure 4b). Interestingly, luminal A
tumors in the luminal-simple subtype showed several dis-
tinct differences compared with luminal A tumors in the
luminal-complex subtype, including lower FGA (P =
0.0005; t test), different CNA pattern (Figure S6 in Addi-
tional File 3), lower genomic-grade correlation (P = 0.02; t
test), lower correlation to the luminal B gene-expression
centroid [4] (P = 0.0005; t test), higher correlation to the
luminal A gene-expression centroid [4] (P = 0.05; t test),
and a trend toward better OS (log-rank, P = 0.06). By
comparison, in the luminal-complex subtype, luminal A
cases showed better OS than luminal B cases (log-rank, P
= 0.02), as well as lower FGA, S-phase fractions, and
genomic grade correlation (P < 0.02; t test).
To confirm the observation that luminal A cases in the
luminal-simple subtype show a trend toward better clini-
cal outcome than other luminal A cases, we created gene-
expression centroids for the genomic subtypes based on
genes from the Hu et al. [4] gene list (Additional File 1).
Gene-expression centroids were subsequently applied to
a previously reported combined Affymetrix BC data set
[14]. For luminal A-classified tumors in the combined
Affymetrix data set, improved DMFS was observed for
luminal-simple samples compared with non-luminal-
simple samples (Figure 4c), further supported by multi-
variate analysis (n = 225, P = 0.004; HR = 0.36; 95% CI =
0.18-0.73) using LN status, ER status, tumor size, and his-
tologic grade (grade 3 versus 1 and 2) as covariates. To
investigate whether luminal-simple-classified luminal A
tumors also showed lower FGA in independent data sets,
we analyzed the Chin et al. [3] aCGH data set by using
the genomic-subtype classification from corresponding
gene-expression data in the combined Affymetrix data
set. Convincingly, for luminal A tumors in the Chin et al.
[3] data set, luminal-simple cases showed lower FGA
than did luminal-complex cases (P = 0.01; t test) and a
trend towards better OS (log-rank, P = 0.16).
High-level amplifications in genomic subtypes
High-level amplifications were observed in 41 of the 66
GISTIC gain regions, involving 139 (39%) of 359 tumors.
Interestingly, none of these belonged to the luminal-sim-
ple subtype. Occurrence of high-level amplifications was
associated with a worse OS (log-rank, P = 0.0007). The
17q12 subtype showed the highest percentage of tumors
with high-level amplifications (78%), followed by the
amplifier (50%), luminal-complex (38%), basal-complex
(34%), and mixed (26%) subtypes. Certain high-level
amplicons were predominantly observed in specific sub-
types: for example, 10p14 (basal-complex), 17q11.2
(17q12 subtype), 17q12 (17q12 subtype), 17q21.33 (17q12
subtype), and 19p13.11 (17q12 subtype). Other ampli-
cons were observed in two subtypes: for example, 8p12
(amplifier, luminal-complex), 11q13.3 and 11q13.5 (lumi-
nal-complex, amplifier), 12p13.31 (basal-complex, ampli-
fier), 6q23.3 (basal-complex, mixed) and 8q24.21
(luminal-complex, basal-complex).
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Figure 4 Supervised analysis in luminal genomic subtypes. (a) Significant Genomic Identification of Significant Targets in Cancer (GISTIC) regions 
between BRCA2-mutated and non-BRCA2 tumors within the luminal-complex subtype. (b) Significant GISTIC regions between the luminal-complex 
and luminal-simple subtypes. (c) Distant metastasis-free survival (DMFS) for luminal A tumors stratified by classification as luminal-simple or non-lu-
minal-simple in a combined Affymetrix gene-expression data set. Significant GISTIC regions were identified by Bonferroni-adjusted Student t test (P < 
0.05); red indicates more-frequent gain, and green indicates more-frequent loss, in comparisons between GISTIC regions. Only significant regions with 
≥20% CNA frequency are displayed.
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BC is a biologically heterogeneous disease and has been
stratified into molecular subtypes by using gene-expres-
sion profiling [1]. These subtypes were subsequently
found to display different clinical outcomes with the
HER2-enriched, basal-like, and luminal B as poor prog-
nostic groups [2]. Several studies have used microarray-
based genome-wide DNA copy-number analysis to
describe recurrent, almost universally affected, chromo-
somal regions on 1q, 8, and 16, but also recognized that
BC is a profoundly heterogeneous disease on the genomic
level [3,21-24].
Here, we used high-resolution BAC aCGH to confirm
the frequent CNAs on chromosomes 1q, 8q, and 16, as
well as recurrent high-level amplifications on 17q12,
11q13, 8p12, and 8q24, encompassing known oncogenes,
as previously described [3]. Although these CNAs may
have a major impact on the progression of a significant
proportion of BC, other amplicons contribute to the
genomic diversity of the disease. For instance, chromo-
some 1q32 was highly amplified in seven (2%) of the 359
tumors and includes the MDM4 gene. A significant cor-
relation was found between gene and transcript levels,
suggesting that MDM4 is a potential oncogene in BC with
a p53-inhibiting function similar to that of MDM2 [25].
Coamplification of chromosomes 8p12 and 11q13.3,
occasionally combined with 11q13.5-q14.1 or 12q15, was
found in a significant fraction of tumors. This suggests
that the targeted genes or oncogenic pathways act syner-
gistically and are advantageous for the tumor: for exam-
ple, CCND1 (11q13.3) targeting the G1/S checkpoint, and
MDM2 (12q15) targeting the p53 pathway. Previous stud-
ies also indicated frequent coamplification of 11q13 and
8p12, in which functional analyses revealed an extended
complexity of these two cooperating genetic events [26].
The GISTIC algorithm [13] also captured other rare high-
level gene amplifications such as the PIK3CA and MYB
loci, genes frequently affected by alternative mechanisms
[27,28], supporting their role in BC development.
Unsupervised hierarchical clustering based on signifi-
cant (GISTIC) CNAs categorized the cohort into six
genomic subtypes with striking similarity to the previ-
ously described gene-expression subtypes and differences
in clinical outcome [1]. Earlier studies recognized three
genomic subtypes in BC, characterized by a 1q/16q com-
plex and amplifier genotype, respectively [3,21]. Their
complex subtype was associated with the basal-like gene-
expression subtype [3], corroborating our observation of
a genomically homogenous basal-complex subtype. The
1q/16q subtype most likely corresponds to our luminal-
simple subtype, whereas we, because of a larger number
of tumors, were able to divide the amplifier subtype [3,21]
further into one homogenous 17q12 subtype comprising
the majority of HER2-amplified cases, a luminal-com-
plex, and an amplifier subtype. The 17q12 subtype was
associated with the worst clinical outcome and was
essentially unified by a few amplified regions on 17q,
including the HER2 locus on 17q12, as discussed in more
detail elsewhere [17]. Moreover, 8p12-amplified tumors
were confined mainly to two genomic subtypes, the
amplifier and luminal-complex subtypes, with high-level
8p12 amplification occurring primarily in the amplifier
subtype. In agreement with the findings by Chin et al. [3],
we found that tumors with gain or loss at the 8p12 GIS-
TIC region displayed inferior survival as compared with
tumors with normal 8p12 copy number (log-rank, P =
0.04 and P = 0.008, respectively).
As expected, 17 of 22 tumors from BRCA1 mutation
carriers were located in the basal-complex subtype, con-
firming the complex genome of BRCA1 tumors [29,30]
and previous gene-expression studies [2]. Interestingly,
no significant CNA difference was found between
BRCA1 and non-BRCA1 tumors in the basal-complex
subtype, indicating an extensive genomic homogeneity in
this genomic subtype. We did observe a significantly
higher FGA in BRCA1 tumors, although it should be
noted that all basal-complex tumors had significantly
higher FGA than did non-basal-complex tumors. These
results may point toward a general DNA-repair defi-
ciency of tumors in the basal-complex subtype, which
may extend recent therapeutic opportunities beyond
patients with a germline BRCA1 mutation [31]. Basal-
complex tumors had frequent copy-number losses on
chromosome 5q, in line with previous studies showing
loss of heterozygosity (LOH) and physical deletions of 5q
in BRCA1 tumors [30,32]. Although a target gene in this
region is still to be identified, several candidates do exist
(for example, PIK3R1 located on chromosome 5q13.1,
previously found to be homozygously deleted in a
BRCA1-mutated tumor) [32].
The majority of BRCA2-mutated tumors were located
in the luminal-complex subtype, the exception being a
few predominantly basal-like and ER-negative BRCA2
tumors that were in the basal-complex subtype. Deletions
on chromosomes 3p, 6q, and 13q14 and gains on 17q
were more frequent in BRCA2 tumors as compared with
other luminal-complex tumors, as also was shown by oth-
ers [30,33], and is somewhat mirrored by the higher fre-
quency of CNAs in BRCA2 tumors. Taken together, in
contrast to the scenario for BRCA1, these results indicate
that specific BRCA2-associated genomic aberrations
exist.
In strong contrast, tumors of the luminal-simple
genomic subtype displayed a stable genome without
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chromosomes 1q and 16q. This subtype included almost
exclusively ER-and PgR-positive tumors of low histologic
grade, and included approximately one third of all lumi-
nal A-classified samples. However, another third of lumi-
nal A tumors were found in the luminal-complex subtype,
and 13%, in the amplifier subtype, suggesting heterogene-
ity within the current gene-expression-based classifica-
tion of luminal A tumors. Luminal A tumors in the
luminal-complex subtype were characterized by a signifi-
cantly higher FGA and higher correlation to the genomic-
grade signature [10], as well as a different pattern of
genomic alterations than luminal A tumors of the lumi-
nal-simple group. Most important, the latter cases
showed a trend toward better survival, supporting the
aim of a clinically meaningful stratification of luminal A
tumors based on their pattern of DNA CNAs.
To test this hypothesis, we constructed gene-expression
centroids for the different genomic subtypes and applied
them to two independent breast cancer gene-expression
data sets. Intriguingly, an improved clinical outcome was
observed for luminal-simple-classified samples within the
luminal A subtype in a large combined Affymetrix data
set, as well as lower FGA in the Chin et al. [3] data set.
Corroborating findings by Chin et al., this strongly sug-
gests that the luminal A subtype could be further divided
based on genomic alterations, warranting further investi-
gation. Previously, reports suggested that a fraction of
histologic grade 3 tumors progressed from grade 1 with
accumulation of genomic aberrations [34,35]. An inter-
esting hypothesis would be that the luminal-simple and
luminal-complex division reflects a tumor-progression
pathway of luminal tumors, as the frequent genomic
aberrations in luminal-simple cases (+1q, -16q) are also
apparent in luminal-complex samples. Moreover, lumi-
nal-complex tumors have additional genomic aberrations
not present in luminal-simple tumors, such as +8q, -11q,
and -13q, suggesting that these represent late genomic
events. However, more in-depth studies are needed to
confirm this.
Conclusions
Six main groups of BC with distinct genomic-aberration
patterns and striking similarity to gene-expression sub-
types were found. BRCA1 tumors were confined to a uni-
form subtype termed basal-complex, characterized by a
high frequency of low-level CNAs, basal-like, ER and
PgR-negative, and histologic grade 3 tumors. BRCA2
tumors clustered among luminal-complex tumors char-
acterized mostly as luminal B, ER-positive, and histologic
grade 2. The genomic subtypes were significantly associ-
ated with clinical outcome, and the observation that
luminal-simple cases display a better disease outcome
within the intrinsic luminal A subtype was validated in
independent data sets. Finally, our data emphasize the
profound molecular heterogeneity in BC. Understanding
the underlying genomic and biologic mechanisms may
prove useful for prognostic as well as treatment-predic-
tion purposes.
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